Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Oct;148(10):2581-2588.
doi: 10.1007/s00432-021-03780-7. Epub 2021 Oct 8.

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma

Felix Schriegel  1 , Sabine Taschner-Mandl  2 , Marie Bernkopf  2 , Uwe Grunwald  3 , Nikolai Siebert  1 , Peter F Ambros  2 , Inge Ambros  2 , Holger N Lode  1 , Guenter Henze  4 , Karoline Ehlert  5
Affiliations

Comparison of three different methods to detect bone marrow involvement in patients with neuroblastoma

Felix Schriegel et al. J Cancer Res Clin Oncol. 2022 Oct.

Abstract

Purpose: Neuroblastoma (NB) is the most frequent extracranial tumor in children. The detection of bone marrow (BM) involvement is crucial for correct staging and risk-adapted treatment. We compared three methods regarding the detection of NB involvement in BM.

Methods: Eighty-one patients with NB were included in this retrospective study. BM samples were obtained at designated time points at study entry and during treatment or follow-up. The diagnostic tools for BM analysis included cytomorphology (CM), flow cytometry (FCM) and automatic immunofluorescence plus fluorescence in situ hybridization (AIPF).

Results: We analyzed 369 aspirates in 81 patients in whom AIPF, CM, and FCM were simultaneously available. During the observation period, NB cells were detected in 86/369 (23.3%) cases, by CM in 32/369 (8.7%), by FCM in 52 (14.1%), and by AIPF in 72 (19.5%) samples. AIPF and/or FCM confirmed all positive results obtained in CM and detected 11 additional positive BM aspirates in 294 CM negative samples (p < 0,001). Survival of patients with BM involvement at study entry identified solely by FCM/AIPF was 17.4% versus 0% for patients in whom BM involvement was already identified by CM.

Conclusion: The combination of AIPF/FCM yielded the highest detection rate of NB cells in BM. AIPF was the single, most sensitive method in detecting these cells. Although CM did not provide any additional positive results, it is still a useful, readily available and cost-effective tool. The prognostic significance of FCM and AIPF should be confirmed in a prospective study with a larger number of patients.

Keywords: Bone marrow; Minimal residual disease; Neuroblastoma; Survival.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there is no conflict of interest.

Figures

Fig. 1
Fig. 1
Flow-chart: bone marrow involvement at study entry and during follow-up
See this image and copyright information in PMC

References

    1. Abbasi MR, Rifatbegovic F, Brunner C et al (2015) Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses. Mol Oncol 9:545–554. 10.1016/j.molonc.2014.10.010 - PMC - PubMed
    1. Ambros PF, Mehes G, Ambros IM, Ladenstein R (2003) Disseminated tumor cells in the bone marrow-chances and consequences of microscopical detection methods. Cancer Lett 197:29–34. 10.1016/S0304-3835(03)00078-8 - PubMed
    1. Aronica PA, Pirrotta VT, Yunis EJ, Penchansky L (1998) Detection of neuroblastoma in the bone marrow: biopsy versus aspiration. J Pediatr Hematol Oncol 20:330–334. 10.1097/00043426-199807000-00010 - PubMed
    1. Beiske K, Ambros PF, Burchill SA et al (2005) Detecting minimal residual disease in neuroblastoma patients-the present state of the art. Cancer Lett 228:229–240. 10.1016/j.canlet.2005.02.053 - PubMed
    1. Beiske K, Burchill SA, Cheung IY et al (2009) Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the international neuroblastoma risk group task force. Br J Cancer 100:1627–1637. 10.1038/sj.bjc.6605029 - PMC - PubMed